Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

An 11-year-old girl with severe hair loss regrew and repigmented her hair after JAK inhibitor treatment.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.

A new genetic mutation in the TRPS1 gene causes Trichorhinophalangeal Syndrome, leading to specific hair, dental, and bone issues.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

A girl with citrullinemia developed pili torti, suggesting a link between the hair condition and the metabolic disorder.

LRIG1 protein affects hair growth by regulating skin receptors, leading to hair loss when overexpressed.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

A girl with Rapunzel syndrome had surgery to remove a hairball, and addressing mental health is important to prevent it from happening again.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

TRH stimulates human hair growth and extends the hair growth phase.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

The trial on testosterone replacement therapy in older men faced concerns due to prostate cancer risk.

Dermatologists should consider congenital syndromes like TRPS in young adults with early hair loss.

CTP-543 is generally safe for treating alopecia areata.

Ritlecitinib is generally safe for long-term use in treating alopecia areata.

The new bioreactor improves skin grafts by evenly stretching cells and monitoring conditions for better growth.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Ritlecitinib shows promise for treating alopecia areata with significant hair regrowth and no serious side effects.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Triptorelin helps evaluate hormone production in Sertoli-Leydig cell tumors.

Combining Proton Minibeam with FLASH Radiotherapy may improve cancer treatment by reducing side effects and increasing effectiveness.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

CTHRC1 is essential for healing and preventing heart rupture after a heart attack.

Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.